HealthCare Global Enterprises reported a consolidated net profit of Rs 9.25 crore for the quarter ended September 30, 2026. On a standalone basis, the company swung to a net loss of Rs 2.04 crore. The results include a one-time exceptional charge of Rs 11.59 crore due to customs duty provisions. Additionally, the company has consolidated Advanced Molecular Imaging Limited as a subsidiary following a stake increase to 50.10%.
HealthCare Global Q2 Results: Consolidated Profit at Rs 9.25 Crore
Standalone net loss stands at Rs 2.04 crore; Consolidated net profit reported at Rs 9.25 crore.
Reader Takeaway: Consolidated profit remains positive despite standalone losses and a significant exceptional charge related to customs duty provisions.
What just happened
HealthCare Global Enterprises Limited released its unaudited financial results for the quarter ended September 30, 2026. The consolidated revenue from operations reached Rs 730.16 crore, while standalone revenue stood at Rs 396.04 crore. The company also disclosed an exceptional charge of Rs 11.59 crore, primarily attributed to estimated customs duty liabilities and associated interest.
Why this matters
The company’s move to consolidate Advanced Molecular Imaging Limited (AMIL) as a subsidiary—following a stake increase to 50.10%—signals a shift in management control. Investors are watching the impact of this consolidation on future margins, especially as the standalone operations moved into a loss position this quarter, contrasting with the profit reported in the same period last year.
What changes now
Effective October 5, 2026, AMIL is treated as a step-down subsidiary, allowing for majority representation on its board. Additionally, the company has initiated the grant of 64,46,843 employee stock options under its HCG ESOS 2026 scheme, which will impact future equity dilution and compensation expenses.
Risks to watch
The primary concern is the standalone net loss of Rs 2.04 crore, which is a decline from the profit of Rs 10.78 crore in the previous year's corresponding quarter. The exceptional charge of Rs 11.59 crore has also weighed on the consolidated bottom line, which fell to Rs 9.25 crore from Rs 20.66 crore year-on-year.
What to track next
Investors should monitor the integration of AMIL into the broader group operations and how the company plans to address the ongoing customs duty liabilities. The long-term impact of the new ESOS grants on employee retention and operational efficiency remains a point of interest.